Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

CorMedix Inc. (CRMD) Market Cap & Valuation Ratios

CorMedix Inc. (CRMD) has a market cap of $611.9M, a trailing P/E of 3.8 and a price-to-sales ratio of 1.3, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CRMDCorMedix Inc.Follow CRMD — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
611.9M
P/E TTM
3.8
Dividend yield
—
52-week
—
Next earnings
11 Nov, in 18 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
CRMD0.63.81.12.0—+281%47%57%
DSGN0.6———-8.6%——-42%
SLDB0.6——————-127%
LXRX0.6—11.9—-10.3%-29%-131%-30%
WVE0.6—4.0——-30%-333%-255%
CADL0.6———-9.3%———
SGMT0.6———-7.0%——-59%
CLYM0.6———-9.3%——-36%
IMMX0.6———-6.7%———
ZVRA0.610.72.74.35.6%+119%61%68%
DBVT0.6—80.2——+29%——
Median of these 1010.77.94.3-8.6%+0.1%-131%-42%

P/E 3.8 vs. a peer median of 10.7; EV/Sales 1.1 vs. 7.9.

Growth vs. price

each dot a company · hover or tap for values

CorMedix Inc. — questions

What is CorMedix Inc.'s market cap?
$611.9M.
What is CorMedix Inc.'s P/E ratio?
3.8 on trailing twelve-month earnings to 2026-06-30.
What is CorMedix Inc.'s price-to-sales ratio?
1.3.

Every figure on this page comes from CorMedix Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.